Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exparel vs Exparel plus Adductor Canal Block in TKA
NCT02365727Phase 4
Key facts
- Status
- Withdrawn
- Start
- Apr 2015
- Primary completion
- Aug 2015
- Countries
- 1
- Sponsor
- The Hawkins Foundation
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands
- Conditions
- knee osteoarthritis (OA)
01
Overview
Phase 4, randomised, double-blind trial of ropivacaine, epinephrine and clonidine in knee osteoarthritis (OA), sponsored by The Hawkins Foundation. Planned start Apr 2015; status: withdrawn.
02
Design
- Study design
- RandomizedDouble-blind
03
Registry description
Patients will be randomized (like the flip of a coin) to receive Exparel and a nerve block, standard of care for this procedure, or Exparel alone for pain management after surgery. They will also be asked to complete questionnaires before surgery, during their stay at the hospital after surgery, then at 3 months, 6 months and 12 months after surgery to assess pain and/or function levels, as well as the amount of pain medicine patients have used after surgery. Patients' leg strength will be measured immediately after surgery and again at 3, 6 and 12 months after surgery.
Beyond the preview
Go deeper on NCT02365727.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365727.